Copyright ©The Author(s) 2021.
World J Transplant. Oct 18, 2021; 11(10): 432-442
Published online Oct 18, 2021. doi: 10.5500/wjt.v11.i10.432
Figure 3
Figure 3 Estimates and 95% confidence intervals from the network meta-analysis comparing the odds of developing post-transplant diabetes mellitus in patients receiving tacrolimus or sirolimus compared to the odds with cyclosporine as the mainstay of treatment. The “All” estimate uses the first time-point from each study. The other estimates are presented according to the timing of that post-transplant diabetes mellitus assessment.